No Yes Ok

Archive

« Older Entries Newer Entries »

THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S Tuesday, June 8th, 2021
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amsterdam, The Netherlands, June 8, 2021 – Yesterday the U.S. FDA (Food [...]
LSP portfolio company binx health raises $104 million Friday, May 28th, 2021
from blue chip investor syndicate to expand its groundbreaking digital business model   Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian [...]
LSP Portfolio Company Artios Pharma Announces Collaboration with Novartis to Create New Cancer Therapies Wednesday, April 7th, 2021
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in addition to near [...]
Binx Health receives FDA CLIA Waiver for Chlamydia and Gonorrhea test Wednesday, March 31st, 2021
expanding critical access to single-visit diagnoses   First ever 30-minute, CLIA-waived, molecular PCR Test for CT/NG now available for OBGYN, physician offices and retail settings holding certificates of wai [...]
Endotronix Celebrates 100th Implant Of The Cordella™ Pulmonary Artery Pressure Sensor Wednesday, March 24th, 2021
For Proactive, Remote Management Of Heart Failure Milestone achieved as company prepares for next stage of commercial growth and expansion   LISLE, Ill., March 23, 2021 /PRNewswire/ -- Endotronix, Inc., a [...]
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing Tuesday, March 23rd, 2021
To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease   Company closes additional $22.6 million in new financing  Proceeds will fund initiation of new clinical trial for lead gene ther [...]
LSP ANNOUNCES CLOSING OF UPSIZED $120 MILLION NASDAQ IPO Thursday, March 18th, 2021
OF EUROPEAN BIOTECH ACQUISITION CORP (EBAC) TARGETING EUROPEAN BIOTECH   EBAC IS THE FIRST HEALTHCARE SPAC TO EXCLUSIVELY FOCUS ON  EUROPEAN BIOTECH EDUARDO BRAVO TO JOIN LSP AS A PARTNER AND BECOM [...]
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV Thursday, March 11th, 2021
a novel personalized cancer immunotherapy   BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today annou [...]
LSP’s portfolio company Simplify Medical acquired by NuVasive Friday, February 26th, 2021
Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine [...]
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients Thursday, February 11th, 2021
Artios Pharma transitions to a clinical-stage precision medicine company Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors   C [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S Tuesday, June 8th, 2021
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amsterdam, The Netherlands, June 8, 2021 – Yesterday the U.S. FDA (Food [...]
LSP portfolio company binx health raises $104 million Friday, May 28th, 2021
from blue chip investor syndicate to expand its groundbreaking digital business model   Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian [...]
LSP Portfolio Company Artios Pharma Announces Collaboration with Novartis to Create New Cancer Therapies Wednesday, April 7th, 2021
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in addition to near [...]
Binx Health receives FDA CLIA Waiver for Chlamydia and Gonorrhea test Wednesday, March 31st, 2021
expanding critical access to single-visit diagnoses   First ever 30-minute, CLIA-waived, molecular PCR Test for CT/NG now available for OBGYN, physician offices and retail settings holding certificates of wai [...]
Endotronix Celebrates 100th Implant Of The Cordella™ Pulmonary Artery Pressure Sensor Wednesday, March 24th, 2021
For Proactive, Remote Management Of Heart Failure Milestone achieved as company prepares for next stage of commercial growth and expansion   LISLE, Ill., March 23, 2021 /PRNewswire/ -- Endotronix, Inc., a [...]
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing Tuesday, March 23rd, 2021
To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease   Company closes additional $22.6 million in new financing  Proceeds will fund initiation of new clinical trial for lead gene ther [...]
LSP ANNOUNCES CLOSING OF UPSIZED $120 MILLION NASDAQ IPO Thursday, March 18th, 2021
OF EUROPEAN BIOTECH ACQUISITION CORP (EBAC) TARGETING EUROPEAN BIOTECH   EBAC IS THE FIRST HEALTHCARE SPAC TO EXCLUSIVELY FOCUS ON  EUROPEAN BIOTECH EDUARDO BRAVO TO JOIN LSP AS A PARTNER AND BECOM [...]
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV Thursday, March 11th, 2021
a novel personalized cancer immunotherapy   BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today annou [...]
LSP’s portfolio company Simplify Medical acquired by NuVasive Friday, February 26th, 2021
Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine [...]
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients Thursday, February 11th, 2021
Artios Pharma transitions to a clinical-stage precision medicine company Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors   C [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund